VSIG4-expressing tumor-associated macrophages impair anti-tumor immunity
- 24 August 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 628, 18-24
Abstract
No abstract availableKeywords
Funding Information
- Inje University
This publication has 24 references indexed in Scilit:
- The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myelomaOncotarget, 2017
- The Significance of VSIG4 Expression in Ovarian CancerInternational Journal of Gynecological Cancer, 2017
- Tumour-associated macrophages as treatment targets in oncologyNature Reviews Clinical Oncology, 2017
- A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic DiseasePLOS ONE, 2012
- Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and natural killer T-cellsHepatology, 2012
- Macrophages From Irradiated Tumors Express Higher Levels of iNOS, Arginase-I and COX-2, and Promote Tumor GrowthInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- VSIG4, a B7 family-related protein, is a negative regulator of T cell activationJournal of Clinical Investigation, 2006
- CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating PathogensCell, 2006
- Development of a syngeneic mouse model for events related to ovarian cancerCarcinogenesis, 2000
- Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.Proceedings of the National Academy of Sciences, 1994